Where does Vistagen Therapuetics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Vistagen Therapuetics, Inc. ranks #27,791 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Vistagen Therapuetics, Inc. hold?

Vistagen Therapuetics, Inc. holds 10 US utility patents granted between 2017 and 2024, spanning 8 technology areas.

What is Vistagen Therapuetics, Inc.'s Innovation Score?

Vistagen Therapuetics, Inc. has an Innovation Score of 26.5 out of 100 (20th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Vistagen Therapuetics, Inc. focus on?

Vistagen Therapuetics, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 6 patents, ranking #2,984 of 6,058 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

Is Vistagen Therapuetics, Inc.'s patent grant rate increasing or decreasing?

Vistagen Therapuetics, Inc.'s recent grant velocity is +50% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Vistagen Therapuetics, Inc.'s patents?

Vistagen Therapuetics, Inc.'s patents average 9.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Vistagen Therapuetics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Vistagen Therapuetics, Inc.

USPTO PatentsView assignee record - 10 granted patents across 8 technology areas, recorded in grant years 2017–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Vistagen ranks #27,791 of 49,997 tracked US assignees by granted-patent volume, with 10 patents across 8 technology areas.

#27,791
of 49,997 US assignees by volume: 20th percentile
by Innovation Score (26.5/100): 9.3
avg claims per patent: +50%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R27791 · US Corporation #27,791 · 10 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 10 grants
MID-PACK #27,791/49,997
PHOTO-FINISH Vhit S p A
CPC-NARROW A61P · 8 areas
INNOV-THIN 26.5/100
CLAIMS-PAR 9.3 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +50% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Vhit S.p.A. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Vistagen’s 26.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.3 pts (31%) Velocity 2.7 pts (10%) Breadth 10.0 pts (38%) Claim depth 5.6 pts (21%)

Qualcomm Incorporated · highest

85
Vistagen Therapuetics · this assignee

27
3D Lighting… · lowest

7

What this shows Vistagen's Innovation Score is 26.5/100 (20th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Vistagen?

Each dot is one of Vistagen’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Vistagen’s own 9.3 claims/patent is at or below the 10.6 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Vistagen vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Vistagen's grants concentrate

Vistagen Therapuetics, Inc. is a focused PatentsView assignee: 8 CPC subclasses with 60% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2020 (3 grants) versus a trough of 1 in 2017. By volume, Vistagen sits between Vhit S.p.A. and Voxy, Inc.

Vistagen's three-year grant acceleration

Vistagen Therapuetics, Inc. shows 2 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Vhit S p A

10
Viking Tech

10
Vishay Sprague

10
Vismunda SRL

10
Vivere

10
Voestalpine VAE

10
Voti

10
Voxy

10
Vistagen Therapue… ◀

10

What this shows Vistagen holds 10 patents at rank #27,748, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Vistagen

By rank, the assignees closest to #27,748 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Vistagen's primary technology class.

Vistagen's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

27 20th percentile higher than 20% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Vistagen Therapuetics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	1	10.0%
2018	2	20.0%
2019	1	10.0%
2020	3	30.0%
2021	1	10.0%
2022	1	10.0%
2024	1	10.0%

Which technologies does Vistagen Therapuetics, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 6

Y02A - Technologies FOR Adaptation TO Climate Change 6

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 6

C07C - Acyclic OR Carbocyclic Compounds 3

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 2

C12Y - Enzymes 2

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 1

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 1

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Vistagen Therapuetics, Inc.'s patent record in context - here's where to go next.

Vistagen Therapuetics, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 60% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #27,791 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Vistagen Therapuetics, Inc. against Vhit S.p.A., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 26.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.